# macular edema secondary to inflammation FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/macular-edema-secondary-to-inflammation

> 5 upcoming FDA catalysts in macular edema secondary to inflammation: tabirafusp (KOD) on Dec 2026 (topline data readout); tabirafusp alfa (KOD) on February 2027 (primary completion); tabirafusp alfa (KOD) on Feb to May 2027 (topline data readout); tabirafusp alfa (KOD) on April 2027 (primary completion); and 1 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Dec 2026 | [Tabirafusp topline data readout](https://sec-api.dev/pdufa/tabirafusp) | KOD | macular edema secondary to inflammation | scheduled | "These forward-looking statements are not based on historical fact and include statements regarding: the planned multi-indication BLA submission for Zenkuda in the fourth quarter of 2026; the planned BLA submission for KS-101 in the second quarter of 2027; acceleration of the tabirafusp development program and the status of enrollment in, and expectations regarding the ALTO study; planned post-hoc analyses to identify patients that can benefit from IL-6 inhibition; and expectations regarding the announcement of topline data December 2026 for KSI-101 in the Phase 3 PEAK study in patients with macular edema secondary to inflammation (MESI)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1468748/000119312526403481/d185059dex991.htm)) |
| February 2027 | [Tabirafusp alfa primary completion](https://sec-api.dev/pdufa/tabirafusp-alfa) | KOD | Macular Edema Secondary to Inflammation | scheduled | "NCT06996080 (A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-02 (ESTIMATED); Lead Sponsor Kodiak Sciences Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06996080)) |
| Feb to May 2027 | [Tabirafusp alfa topline data readout](https://sec-api.dev/pdufa/tabirafusp-alfa) | KOD | Macular Edema Secondary to Inflammation | scheduled | "NCT06996080 (A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-02 (ESTIMATED); Lead Sponsor Kodiak Sciences Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06996080)) |
| April 2027 | [Tabirafusp alfa primary completion](https://sec-api.dev/pdufa/tabirafusp-alfa) | KOD | Macular Edema Secondary to Inflammation | scheduled | "NCT06990399 (A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-04 (ESTIMATED); Lead Sponsor Kodiak Sciences Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06990399)) |
| Apr to Jul 2027 | [Tabirafusp alfa topline data readout](https://sec-api.dev/pdufa/tabirafusp-alfa) | KOD | Macular Edema Secondary to Inflammation | scheduled | "NCT06990399 (A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-04 (ESTIMATED); Lead Sponsor Kodiak Sciences Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06990399)) |

## Drugs

- [Tabirafusp](https://sec-api.dev/pdufa/tabirafusp) (KOD)
- [Tabirafusp alfa](https://sec-api.dev/pdufa/tabirafusp-alfa) (KOD)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/macular-edema-secondary-to-inflammation.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "macular edema secondary to inflammation FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/macular-edema-secondary-to-inflammation

```bibtex
@misc{secapidev_indications_macular_edema_secondary_to_inflammation_20261116,
  title        = {macular edema secondary to inflammation FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/macular-edema-secondary-to-inflammation}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_macular_edema_secondary_to_inflammation_20261116","title":"macular edema secondary to inflammation FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/macular-edema-secondary-to-inflammation","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
